| 1) | Introduction |
|----|--------------|

| 2) | Scope of      Work: Deliverables, Timing,Resources |
|----|----------------------------------------------------|

----

| Campaign         | Activity                                                                                                                                                                                                                                                                                                                                                                                                                                  | Timing                                 |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Phase      1[**] |  ·          [**]·          [**]                                                                                                                                                                                                                                                                                                                                                    | [**])                                  |
|             |                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                   |
| Phase      2[**] |  ·          Preparation and procurement of raw materials·          [**] drafts batch record for pilot plant scale manufacturing of      [**].  Timing dependent on customer review and      approval.·          [**]·          QC testing and release at Pharmacyclics.·          QA release. | [**][**]   [**][**][**] |

----

| 3) | Analytical      Methods and Specifications |
|----|--------------------------------------------|

|   | a. | Method      Transfer: |
|--------|----|-----------------------|

|   | b. | Specifications      for [**]: |
|--------|----|-------------------------------|

|   |
|--------|
|   |
|   |

| 4) | Documentation      / Reports |
|----|------------------------------|

----

| 5) | Packaging/Labeling/Shipment |
|----|-----------------------------|

| 6) | Pricing |
|----|---------|

| 7) | Terms      and Conditions |
|----|---------------------------|

|   | a) | This      Agreement will serve as the supply agreement referred to in Section 4.3 of      the Collaboration Agreement. A purchase order has been signed and purchase      will be made under purchase order [**]. Terms or conditions of any      purchase order, acknowledgement, or other form given or received that are      additional to or inconsistent with this Agreement or such purchase order      [**] shall have no effect and such terms and conditions are hereby      excluded. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | The current      estimated costs per the contracts established to produce the desired [**]      of [**] are $[**] |
|--------|----|-------------------------------------------------------------------------------------------------------------------|

----

|   | c) | All prices      are in US dollars. |
|--------|----|------------------------------------|

|   | d) | This      Agreement is effective as of the signature date of this agreement      (“Effective Date”) and unless terminated otherwise in accordance with      Section (i) below, shall be in effect until the first to occur of      (i) delivery to Servier of the [**] batches of [**] as contemplated      in Section 2 above, or (ii) termination of the Collaboration      Agreement. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | e) | Pharmacyclics      and its Third Party Manufacturer(s) will, in accordance with the      Collaboration Agreement, apply Reasonable Efforts using the current      synthetic route or process.  In the event that yields or      purities obtained are contrary to those provided due to but not limited to      difficulties of scale, chemistry inconsistencies or misrepresentation,      Pharmacyclics and Servier will mutually agree to discuss pathways to      proceed with the project. These discussions may potentially require scope      changes to the program, extension of the project timeline, and additional      monetary funds. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | f) | If there are      unforeseen complications due to the nature of the project that      significantly hinders Third Party Manufacturer’s ability to proceed with      the completion of this project, Pharmacyclics will notify Servier of any      such difficulties and the parties agree to act in good faith to resolve      difficulties in an amicable manner. The project may require scope changes      to the program, additional monetary funds and timeline extensions to      properly proceed with the project. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | g) | Servier      understands that the quantity requirement stated in the Agreement is a      nominal target output based on conversion of appropriate amounts of      starting materials.  Servier will purchase the material at the      following conditions: |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | [**] |
|--------|---|------|

|   | - | [**] |
|--------|---|------|

|   | - | [**]. |
|--------|---|-------|

|   | h) | Servier has      reviewed and agrees to accept [**] that conforms to the specifications      listed in Section 3) b. above. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------|

|   | i) | In the event      of a party’s material breach of this Agreement, the non-breaching party      shall have the right to provide notice of its intention to terminate this      Agreement.  Such notice shall specify in reasonable detail the      facts and circumstances constituting the material breach of this      Agreement. Upon the expiration of ninety (90) days after receipt by the      breaching party of such notice, if the breaching party has not cured such      material breach, the non-breaching party shall have the right to terminate      this Agreement by giving a notice of termination, which shall be effective      on the date such notice is given. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | j) | In the event      of project termination not due to a material default of Pharmacyclics or      [**], Servier agrees to pay Pharmacyclics all direct costs incurred such      as pass through costs associatedwith: |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 8) | Warranty      and Limitation of Liability |
|----|-------------------------------------------|

|   | A. | Pharmacyclics      represents and warrants to Servier that  (a) it has the full      power and right to enter into this Agreement and that there are no      outstanding agreements, assignments, licenses, encumbrances or rights of      any kind held by other parties, private or public, inconsistent with the      provisions of this Agreement, (b) the services shall be performed with      requisite care, skill and diligence, in accordance with Applicable Laws      and industry standards, and by individuals who are appropriately trained      and qualified. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | B. | Pharmacyclics      represents and warrants to Servier that, at the time of delivery to      Servier, the product supplied under this Agreement (a) will have been      manufactured in accordance with cGMP and all other Applicable Laws, the      Manufacturing Process, the applicable Quality Agreement, and      Specifications, and (b) will not be adulterated or misbranded under the      Food, Drug and Cosmetic Act or other Applicable Laws as the direct result      of Pharmacyclics’ Third Party Manufacturer’s failure to manufacture in      accordance with cGMP or the manufacturing  process. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | C. | Pharmacyclics      represents and warrants to Servier it has not used nor shall use in any      capacity  the services of any persons employed by it’s Third      Party Manufacturer who have been debarred under 21 U.S.C. U.S.C. § 335(a)      or 335(b) in connection with the manufacture of the    product. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | D. | Pharmacyclics      has contracted with Third Party Manufacturers to have [**] manufactured on      Servier's behalf. Pharmacyclics' Third Party Manufacturers' liability      under such contracts is limited to replacement of non-conforming products;      therefore Pharmacyclics can only provide the same limited recourse to      Servier.  Consequently, notwithstanding anything to the contrary      in this Agreement, Servier's sole recourse under this Supply Agreement is      the replacement of a batch(s) by Pharmacyclics, free of      charge. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | E. | This      Agreement is subject to the disclaimer of consequential damages contained      in Section 10.4.1 (Limitation of Liability) of the Collaboration      Agreement |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9) | Miscellaneous. |
|----|----------------|

|   | The      relationship of the parties shall be that of independent      contractors.  This Agreement, including its exhibits, together      with the Collaboration Agreement, sets forth the entire agreement between      the parties with respect to the subject matter contained herein and      supersedes any previous understandings, commitments or agreements, whether      oral or written.  This Agreement may only be amended with a      writing signed by authorized representatives of both parties hereto that      specifically and expressly refers to this Agreement.  A waiver      by any party of any of the terms and conditions of this Agreement in any      instance will not be deemed or construed to be a waiver of such term or      condition for the future, or of any subsequent breach hereof. The parties      may not assign or otherwise transfer its rights and obligations hereunder      without the prior written approval of the other party, provided that no      such consent shall be required for a party to transfer or assign this      Agreement to a party that succeeds to all or substantially all of the      assigning party’s business or assets relating to this Agreement whether by      sale, merger, operation of law or otherwise; provided that such assignee      or transferee promptly agrees in writing to be bound by the terms and      conditions of this Agreement.  This Agreement may be executed in      counterparts, each of which shall be deemed an original, but which      together shall constitute one and the same  document. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| PHARMACYCLICS,      INC.995 E. Arques      AvenueSunnyvale,      California  94085-4521 |                      | Les      Laboratoires Servier22      Rue Garnier92200 Neuilly      sur Seine CedexFrance |
|---------------------------------------------------------------------------------------------------|---------------------------|------------------------------------------------------------------------------------------|
|                                                                                              |                      |                                                                                     |
|                                                                                              |                      |                                                                                     |
|                                                                                              |                      |                                                                                     |
| By:                                                                                               | /s/ Robert W.      Duggan |                                                                                     | By: | /s/ Christian      Bazantay |
|                                                                                              | Name:                     | Robert W.      Duggan                                                               |   |   | Name: | Christian      Bazantay  |
|                                                                                              | Title:                    | Chairman      & CEO                                                                  |   |   | Title: | Proxy |
|                                                                                              |                      |                                                                                     |
|                                                                                              |                      |                                                                                     |
|                                                                                              |                      |                                                                                     |
| Date:       18th, December 2009                                                              |                      | Date:       10th December, 2009                                                     |

----

| 1) | Quality      Standards |
|----|------------------------|

|   | i) | MATERIALS |
|--------|----|-----------|

|   | (1) | Materials      will be ordered against definedspecifications. |
|--------|-----|---------------------------------------------------------------|

|   | (2) | All raw      materials will be received with a supplier’s Certificate of      Analysis.  Pharmacyclics will review and approve raw material      specifications for defined rawmaterials. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | All raw      material batches, for use in cGMP production, will be sampled from their      final packaging and QC released prior touse. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------|

|   | (4) | All raw      material tests and methods will be fully  documented. |
|--------|-----|--------------------------------------------------------------------|

|   | (5) | The identity      and quality status of all materials will be  traceable. |
|--------|-----|---------------------------------------------------------------------------|

|   | (6) | All      materials, intermediates, and finished products will be labeled with an      identity and test status. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------|

|   | ii) | EQUIPMENT |
|--------|-----|-----------|

|   | (1) | All equipment      used for cGMP manufacturing will be maintained in a qualified and      controlled state. |
|--------|-----|-------------------------------------------------------------------------------------------------------------|

|   | (2) | Equipment      will be qualified and maintained to ensure  performance. |
|--------|-----|-------------------------------------------------------------------------|

|   | (3) | If equipment      is used for measurement or inspection, it will be calibrated or verified      to ensure operation within defined  specifications. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (4) | Multi purpose      equipment may be utilized, following Standard Operating Procedures      including appropriately validated or verified cleaning      procedures. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | iii) | Appropriately      trained personnel will carry outmanufacture. |
|--------|------|-----------------------------------------------------------------|

| 2) | QA      / Product Release |
|----|---------------------------|

----

|   | a) | Full details      of all cleaning, processing, and testing will be  recorded. |
|--------|----|-------------------------------------------------------------------------------|

|   | b) | Product      specific Batch Records will be used in all manufacturing operations.      Deviations will be documented and subject to Quality Assurance      approval.  Pharmacyclics Operations and Quality Assurance will      review and approve Mater Batch Record and any major deviation from      approved procedures in the Master Batch Record.  Pharmacyclics      will approve any process changes. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | Process      change control will apply. All relevant observations made during the      processing will be documented. Any deviations from the batch record will      be documented. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | d) | Full batch      record documentation will be completed and approved by Quality      Assurance.  Pharmacyclics Chemical Operations and Quality      Assurance will also review and approve batch history    records. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | e) | Intermediate      product(s) will be tested and the batch records reviewed by appropriate      Third Party Manufacturer. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------|

|   | f) | Third Party      manufacture(s) will retain analytical samples per  SOP. |
|--------|----|--------------------------------------------------------------------------|

|   | g) | Copies of      completed batch records may be provided upon  request. |
|--------|----|-----------------------------------------------------------------------|

| 3) | Final      Product Specifications |
|----|-----------------------------------|

|   | a) | Product shall      comply with the product specifications provided by Pharmacyclics and      Servier. |
|--------|----|-------------------------------------------------------------------------------------------------------|

|   | b) | Additional      test methods and/or specifications could be added, after appropriate data      gathering, technical, and businessdiscussions. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------|

----